Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136408 | 0.92 | THRB (0.44) | THRBSMN1; SMN2LMNAKDM4EMEN1 | |
| SCHEMBL966199 | 0.86 | EPHX1 (0.37) | SMN1; SMN2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL965370 | 0.80 | HPGD (0.37) | SMN1; SMN2LMNAKDM4EKMT2AGAA | |
| SCHEMBL963002 | 0.80 | — | — | |
| SCHEMBL965469 | 0.78 | MEN1 (0.48) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL1693053 | 0.72 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL1693036 | 0.70 | — | — | |
| SCHEMBL482045 | 0.70 | — | — | |
| SCHEMBL2334924 | 0.69 | CYP2D6 (0.40) | LMNACYP2D6 | |
| SCHEMBL16936697 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | THRB 3114/4885SMN1; SMN2 3970/4885LMNA 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.